Standards of Care Guidelines for Thalassemia

1. Overview

Thalassemia comprises a group of inherited hemoglobin disorders characterized by reduced or absent synthesis of one or more globin chains. The clinical spectrum ranges from silent carriers to severe transfusiondependent disease (thalassemia major) and milder, nontransfusiondependent forms (thalassemia intermedia, thalassemia with HbH disease). Modern management aims to improve survival, quality of life, and reduce diseaserelated complications through a multidisciplinary approach.

2. Diagnosis and Screening

2.1 Newborn and Prenatal Screening

• Universal newborn screening where feasible, using highperformance liquid chromatography (HPLC) or capillary electrophoresis to detect abnormal hemoglobin patterns.
• Prenatal diagnosis by chorionic villus sampling or amniocentesis with DNA analysis for known familial mutations.

2.2 Confirmatory Testing

For individuals with abnormal screening results:

• Complete blood count (CBC) with red cell indices.
• Quantitative hemoglobin analysis (HPLC/CE).
• Molecular genetic testing to identify specific or globin gene mutations.

2.3 Carrier Identification

Family screening is recommended for all confirmed patients. Genetic counseling should be offered to carriers of clinically significant mutations.

3. Treatment Modalities

3.1 Red Blood Cell Transfusion

Indications:

• Hemoglobin < 7g/dL in infants, < 8g/dL in older children with symptomatic anemia.
• Growth failure, delayed puberty, or documented organ ischemia.

Goals:

• Maintain pretransfusion hemoglobin 910g/dL (thalassemia major) to suppress ineffective erythropoiesis.
• Use leukoreduced, phenotypically matched blood to reduce alloimmunization.

3.2 Iron Chelation Therapy

Initiate when serum ferritin > 1000ng/mL or after 1020 transfusions.

Combination therapy may be used for severe overload or when monotherapy is insufficient.

3.3 Hematopoietic Stem Cell Transplant (HSCT)

Highest curative potential, especially from HLAmatched sibling donors. Recommended for children < 14years with good organ function. Pretransplant assessment includes cardiac MRI, liver iron quantification, and infectious disease screening.

3.4 Gene Therapy

Emerging option using lentiviral addition or CRISPRbased editing. Indications currently limited to clinical trial participants; longterm safety data are still accruing.

3.5 Management of Complications

• Cardiac disease: Annual cardiac MRI T2*; initiate chelation intensification if T2* < 20ms.
• Endocrine dysfunction: Monitor growth, puberty, thyroid, and glucose tolerance every 612months.
• Bone health: Dualenergy Xray absorptiometry (DXA) every 23years; supplement calcium/vitamin D as needed.
• Hepatic disease: MRIbased liver iron concentration; consider antiviral therapy for hepatitis B/C.

4. Monitoring and Followup

4.1 Routine Laboratory Tests

• CBC and reticulocyte count every 24weeks in transfusiondependent patients.
• Serum ferritin every 3months; correlate with MRI iron studies.
• Renal and hepatic panels every 36months while on chelators.

4.2 Imaging

• Cardiac MRI T2* every 12years.
• Liver iron concentration MRI annually.
• Ultrasound for splenomegaly and gallstones as clinically indicated.

4.3 Transition to Adult Care

Begin structured transition planning at age 1214years. Provide written summary of disease history, treatment regimen, and monitoring schedule to the adult team.

5. Psychosocial Care

Comprehensive care includes mental health, educational support, and family counseling.

• Screen for anxiety and depression at each clinic visit using ageappropriate tools.
• Provide access to social workers versed in insurance, employment, and disability resources.
• Encourage participation in patient advocacy groups and peer support programs.

6. Research and Future Directions

Key areas under active investigation:

• Optimizing geneediting delivery methods to achieve durable, transfusionindependent hemoglobin production.
• Novel oral chelators with improved safety profiles and adherence.
• Biomarkers for early detection of cardiac fibrosis before MRI changes.
• Healtheconomic analyses of curative therapies versus lifelong conventional management.

Clinicians are encouraged to enroll eligible patients in clinical trials and to contribute data to international registries such as the Thalassemia International Federation (TIF) Registry.